What PLT Tablets Treat: Main Uses and Benefits

PLT Tablets are applied across domains where additional symptomatic support is needed, particularly in certain chronic conditions characterized by periods of heightened symptoms. The main uses focus on providing support that helps ease the overall symptom burden. It is relevant for managing symptoms that create noticeable physiological strain and interfere with daily comfort, and may be used in situations involving distressing symptoms. The application of this medication is related to conditions presenting with systemic or localized discomfort, such as osteoarthritis.

The medicine is applicable within clinical settings that involve acute or unstable symptom patterns. The supportive assistance offered may contribute to improved day-to-day comfort and helps maintain a sense of stability during symptomatic episodes. The symptomatic support offered is considered relevant in conditions characterized by periods of heightened symptoms, supporting general well-being during symptomatic phases.

“Applied during phases of increased distress or discomfort, it supports patients during difficult episodes by easing distress.”

Quick Fact: Relief for Physiological Strain

Regulatory References

1. UK Veterinary Medicines Directorate (VMD) official product information

PLT Tablets are officially designated as a combination anti-inflammatory agent with eligibility strictly defined by regulatory authorities. The medicine is primarily approved for use in the dog as a Veterinary Medicinal Product. Use in any other animal species is formally contraindicated by official product labeling.

Eligibility Scope

Condition-Specific Eligibility Rules

Use is also strictly prohibited for individuals with specific pre-existing health conditions or during concurrent therapy. The official label specifies that PLT Tablets must not be used in cases of severe nephrosis (severe kidney disease), hepatitis (liver inflammation), or circulatory congestive conditions.

Furthermore, the medicine is contraindicated for users with a history of adverse reaction to a steroid or NSAID treatment, and those receiving diuretic therapy or other NSAIDs or steroids. This structured regulatory profile formalizes who is eligible and who is non-eligible based entirely on governmental documentation.

Interactions with other medicines and products

The official regulatory profile for PLT Tablets is primarily defined by specific interaction-related prohibitions and mandatory administration requirements documented in government product information. The key constraint is the classification of certain medicinal product categories as formally prohibited combinations.

The co-administration of PLT Tablets with any of these three distinct product classes is designated as Contraindicated in official regulatory documents, reflecting an officially acknowledged additive risk profile. This classification represents the highest level of restriction within the interaction domain.

The regulatory interaction profile explicitly states that no known interactions are documented concerning specific pharmacokinetic mechanisms, such as those mediated by metabolic enzymes (e.g., CYP pathways) or drug transporters. Similarly, no population-specific cautions regarding altered interaction severity are noted in the official documentation. Therefore, the documented structure of the interaction profile centers entirely on these identified contraindicated medicinal product categories and the explicit timing rule involving mandatory food co-administration, as mandated by the government health authorities.

PLT Tablets exert their action through a coordinated, dual-mechanism intervention on the inflammatory signaling cascade. The Cinchophen component achieves non-selective inhibition of Cyclooxygenase (COX-1 and COX-2) enzymes, directly suppressing the formation of prostaglandins. Simultaneously, Prednisolone acts as an agonist for the intracellular Glucocorticoid Receptor (GR). This activation initiates genomic changes, leading to the transrepression of pro-inflammatory transcription factors, such as NF-κB, and the induction of proteins like Lipocortin-1 which inhibit Phospholipase A2 (PLA2). This combined effect results in a dual-point blockade of the Arachidonic Acid cascade, decreasing fluid and protein extravasation and initiating the rapid modulation of nociceptive signaling. The overall action profile is shaped by the kinetic difference between the rapid, non-genomic Cinchophen mechanism and the slower, genomic Prednisolone mechanism, dictating the time lag for the full magnitude of systemic action to manifest.

PLT Tablets are formulated as tablets intended solely for oral administration. The usage of this combination medication is strictly governed by a structured, weight-dependent protocol. The required dosage is not fixed per tablet but is calculated according to the patient's body weight, demanding 25 mg of Cinchophen and 0.125 mg of Prednisolone per kilogram of body weight. This prescriptive regimen necessitates the use of the 200 mg/1 mg tablets, which are double-scored to allow for precise fractional dosing when needed to meet the calculated weight requirement.

The administration pattern is set at a frequency of twice daily. It is a mandatory instruction that the dose should be co-administered with food as part of the established usage conditions. Furthermore, the overall use of the medicine is designed as an intermittent, cyclic protocol, not a continuous one.

The initial period of use is strictly limited to a duration not exceeding 14 days. Following the completion of this initial course, a mandatory 14-day treatment-free interval must be observed before any further use can be resumed. A crucial procedural constraint tied to proper use is the requirement to discontinue therapy and re-assess the patient if no clinical improvement has been demonstrated after the first 3 days of administration. These specific instructions define the authorized use-cycle for this combination medicine.

Overview of Studies and Research Evidence for PLT Tablets

This section summarizes the official research evidence that describes the clinical evaluation of PLT Tablets. It explains the types of studies conducted and what broad conclusions regulatory bodies rely upon, focusing on what research has explored and what remains uncertain according to scientific and governmental sources.

Evidence for Use in Osteoarthritis Symptom Support

The research directly studying the Cinchophen and Prednisolone combination product primarily was evaluated in studies that examined the symptoms associated with Osteoarthritis. These assessments were typically Controlled Clinical Trials documented in official regulatory submissions. These studies explored outcomes related to physical discomfort and functional imbalance within the studied population (Canines with naturally occurring Osteoarthritis).

Specifically, research examined functional measurements such as lameness scores, joint mobility measures, and weight-bearing capacity. Findings describe patterns observed in the studies over the defined time intervals. Research highlights changes measured during the study period in these functional outcomes, indicating that the medicine was studied to measure changes in some of the outcomes linked to inflammatory or irritative states.

Evidence from Related Studies in General Inflammatory Conditions

The Prednisolone component of PLT Tablets is a corticosteroid, a drug class that was evaluated in an extensive body of evidence (including Randomized Controlled Trials and Systematic Reviews) that explored various conditions characterized by fluctuating or episodic manifestations of systemic inflammation.

This body of research was evaluated to assess outcomes related to systemic or functional imbalance across diverse adult human populations. The evidence suggests the corticosteroid component was studied to assess changes in measurements of inflammation in related human diseases. These findings indicate the corticosteroid component was associated with changes in outcomes capturing phases of heightened symptom activity and outcomes reflecting daily functioning.

What is Still Uncertain About the Research for PLT Tablets

Evidence highlights what is known, and what is still uncertain. A key uncertainty is the limited research evaluating outcomes in human populations and the modern clinical data on the Cinchophen component. Data for certain groups remain insufficient, particularly in specific human subgroups or in clinical scenarios outside of the primary licensed use for the combination.

The follow-up durations were limited in the primary combination studies, typically covering only the initial treatment phase (e.g., up to 14 days), meaning that long-term effects are not fully established based on the available combination studies. The research provides insight into short-term changes, but does not describe maintenance data or long-term patterns of measured change for the two-drug product.

Key Studies & References

1. Summary of Product Characteristics (SPC) for PLT Tablets (Veterinary Medicines Directorate, UK)
2. Pharmacokinetics and clinical efficacy of a cinchophen and prednisolone combination tablet in the dog (Abstract/Research Profile Summary)

Common questions about PLT Tablets (FAQ)

Q: What are the main benefits people report from taking PLT Tablets?

A: The official product purpose is to support symptom management associated with inflammatory conditions. Studies examined changes in functional measurements, such as joint mobility and reduced lameness, in the studied population. This dual-action medicine is intended to offer robust support for comfort and mobility.

Q: How quickly should I expect to feel the effect of PLT Tablets?

A: The drug's official mechanism is a combination of fast- and slow-acting components. The regulatory protocol specifies that re-evaluation by a medical professional is necessary if no clinical improvement is observed after the first 3 days of administration.

Q: How long does the effect of a single dose of PLT Tablets last?

A: The administration instructions specify a frequency of twice daily. This schedule dictates the intended interval between doses to maintain the required therapeutic level.

Q: Do PLT Tablets affect sleep patterns?

A: The Prednisolone component is a corticosteroid. Adverse event reports for this class of medicine have included psychiatric effects, such as anxiety, restlessness, and problems sleeping. This information is noted in regulatory summaries.

Q: Are there any specific foods or drinks I should avoid while taking PLT Tablets?

A: The regulatory documentation specifies that the tablets must be co-administered with food. No specific food or drink items are listed as being contraindicated in the official product information.

Q: What are the warning signs of a serious side effect from PLT Tablets?

A: The regulatory label advises that signs such as vomiting, diarrhoea, jaundice (yellowing), or general dullness should prompt immediate discontinuation of the medicine and re-examination by a medical professional. Gastro-intestinal ulceration is a known risk with similar drugs.

Q: Do PLT Tablets change the results of any common lab tests?

A: The corticosteroid component can lead to changes in certain laboratory test results, including increased levels of liver enzymes. It may also suppress the Hypothalamic-Pituitary-Adrenal (HPA) axis, which is part of the body's natural stress response system.

Q: Is PLT Tablets suitable for long-term use?

A: The official regulatory protocol dictates an intermittent, cyclic use, not continuous therapy. Available research primarily focuses on short-term use, and long-term effects have not been fully established in the available combination studies.

Q: How are PLT Tablets usually packaged?

A: The tablets are manufactured as fawn-coloured pills. The official product description notes that they are typically marked with 'PLT' on one side and feature a double-score line on the other.

Q: Does taking PLT Tablets require regular blood monitoring?

A: Because the corticosteroid component has the potential to affect liver enzymes and blood-related parameters, regular assessments may be part of the care plan determined by a medical professional during treatment.

Q: Why do some people need to take a lower dose of PLT Tablets?

A: Official administration instructions specify that the required dose is calculated according to the patient’s body weight. This weight-dependent protocol results in precise, individualized doses.

Q: Do PLT Tablets cause changes in mood or anxiety?

A: The Prednisolone component is a corticosteroid. Regulatory summaries for this drug class include reports of psychiatric side effects, such as changes in mood, restlessness, and anxiety.

Q: Can PLT Tablets be used for pets (e.g., dogs or cats)?

A: Regulatory classification identifies PLT Tablets as a Veterinary Medicinal Product. The medicine is approved for use only in the dog, and use in any other animal species, including cats, is formally contraindicated by the official product label.

How to Store and Dispose of PLT Tablets?

PLT Tablets must be stored strictly according to the official regulatory requirements to maintain their quality and effectiveness.

Storage Requirements

Disposal Instructions

Official government guidelines require that any unused PLT Tablets and all empty packaging be disposed of safely. Do not dispose of this medicine in household trash or wastewater unless specifically instructed by a healthcare provider or regulatory program. Instead, dispose of all unused product and empty containers in accordance with the guidance provided by your local waste regulation authority or a drug take-back program, if available.